Company Analysis
Sign in

Theriva Biologics, Inc. (TOVX)

NYSE: TOVX · Pharmaceutical Preparations · Rockville, MD · filing with the SEC since 1996
Full chart Alerts Compare
Grade4.4
◀ Past 3.6● Present 4.2▶ Future 5.1
6 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

54 patents granted to the 6 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Theriva Biologics, Inc.’s names, not what it holds today.

Patents granted
54
54 utility, 1976 to Dec 31, 2025
Granted in 2025
4
Against 6 in 2024 and 4 in 2023
Applications published
78
3 of them in 2025
Names they are printed under
6
a former name, its own name
By yearGrantedApplications published
'02'03'11'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals16
Biotechnology3
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name6 counted
Synthetic Biologics, Inc. a former name
named as the applicant on its applications, in US
0 granted
54 published
Synthetic Biologics, Inc. a former name
US, as the owner printed on each patent
37 granted
8 published
Theriva Biologics, Inc. its own name
named as the applicant on its applications, in US
0 granted
15 published
Theriva Biologics, Inc. its own name
US, as the owner printed on each patent
13 granted
0 published
Sheffield Pharmaceuticals, Inc. a former name
US, as the owner printed on each patent
4 granted
0 published
ADEONA PHARMACEUTICALS, INC. a former name
US, as the owner printed on each patent
0 granted
1 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 30, 202512,508,304Alkaline phosphatase formulationsPharmaceuticalsTheriva Biologics, Inc.
Nov 18, 202512,472,147Intestinal alkaline phosphatase formulationsPharmaceuticalsTheriva Biologics, Inc.
Jun 3, 202512,318,434Alkaline phosphate-based oncology treatmentsPharmaceuticalsTheriva Biologics, Inc.
Apr 15, 202512,274,740Microbiome protection from oral antibioticsPharmaceuticalsTheriva Biologics, Inc.
Dec 31, 202412,178,917Beta-lactamase formulations and uses thereofPharmaceuticalsTheriva Biologics, Inc.
Jul 30, 202412,048,735Alkaline phosphatase formulationsPharmaceuticalsTheriva Biologics, Inc.
May 14, 202411,981,899E. coli-based production of beta-lactamaseBiotechnologyTheriva Biologics, Inc.
Apr 2, 202411,944,669Method and compositions for inhibiting or preventing adverse effects of oral antibioticsPharmaceuticalsTheriva Biologics, Inc.
Jan 30, 202411,883,474Microbiome protection from oral antibioticsPharmaceuticalsTheriva Biologics, Inc.
Jan 16, 202411,872,268Safe and effective beta-lactamase dosing for microbiome protectionPharmaceuticalsTheriva Biologics, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Oct 30, 20252025/0332230ULCERATIVE COLITIS TREATMENTS IN SELECTED PATIENTSPharmaceuticalsTheriva Biologics, Inc.
Aug 28, 20252025/0268993ALKALINE PHOSPHATE-BASED ONCOLOGY TREATMENTSPharmaceuticalsTheriva Biologics, Inc.
Jan 2, 20252025/0000953ALKALINE PHOSPHATASE FORMULATIONSPharmaceuticalsTheriva Biologics, Inc. · patent 12,508,304 granted from it
Aug 15, 20242024/0269247MICROBIOME PROTECTION FROM ORAL ANTIBIOTICSPharmaceuticalsTheriva Biologics, Inc. · patent 12,274,740 granted from it
Aug 1, 20242024/0252599ALKALINE PHOSPHATASE-BASED TREATMENTS OF CELIAC DISEASEPharmaceuticalsTheriva Biologics, Inc.
Jun 20, 20242024/0197842METHOD AND COMPOSITIONS FOR INHIBITING OR PREVENTING ADVERSE EFFECTS OF ORAL ANTIBIOTICSPharmaceuticalsTheriva Biologics, Inc.
Mar 14, 20242024/0082370SAFE AND EFFECTIVE BETA-LACTAMASE DOSING FOR MICROBIOME PROTECTIONPharmaceuticalsTheriva Biologics, Inc.
Dec 21, 20232023/0405099METHOD AND COMPOSITIONS FOR INHIBITING OR PREVENTING ADVERSE EFFECTS OF ORAL ANTIBIOTICSPharmaceuticalsTheriva Biologics, Inc. · patent 11,944,669 granted from it
Dec 14, 20232023/0398194METHODS AND COMPOSITIONS FOR ATTENUATING ANTIBIOTIC RESISTANCEPharmaceuticalsTheriva Biologics, Inc.
Oct 19, 20232023/0332128MODIFIED BETA-LACTAMASES AND METHODS AND USES RELATED THERETOPharmaceuticalsTheriva Biologics, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 7.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton TOVX · research, not advice